molecules of the month

August 2022

A covalent KRASG12R inhibitor used as a proof-of-concept for covalent arginine modification, an oral dihydroorotate dehydrogenase inhibitor being developed for acute myelogenous leukemia, and a first-in-class YAP-TEAD protein-protein are some examples of this month's MOTM.

In the slide deck, you'll find a compound that has over 1400-fold selectivity for Cathepsin K over other biologically relevant cathepsins and a hydroxylated compound that is more than 1900x more selective than its non-hydroxylated counterpart.

Check out all ten minireviews in the slide deck, which covers:

  • Where are the Molecules of the Month in clinical development?
  • What's known about differentiation from previous molecules?
  • Where did the starting points come from?
  • Industry context, mechanism of action details, and more…

Thanks to reviewers Dennis Koester and Bryan McKibben for their nominations and commentary this month.

A slide deck with more details about each molecule is available.

Upgrade Membership to Download Slide Deck

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

Newsletter

nominate a molecule

Encountered an interesting new molecule? Let your community know!

become a reviewer

Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.

past molecules of the month

Check out previous selections below.

molecules of the year nominees

Previous selections for Drug Hunter’s Molecule of the Year below.

hall of fame
molecules of the year

Previous selections for Drug Hunter’s Molecule of the Year below.

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

Newsletter

Join Subscribers from